Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 13-sep-2026 · last seen 13-sep-2026

Myostatin/Activin Pathway Inhibitors

Current understanding

To be populated as evidence accumulates.

Evidence log

Open questions

Related

Contributing findings

pubmed trial early human-rct
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026 novelty 4 per-area 4 strengthens
pubmed review
Targeting skeletal muscle wasting: Emerging therapeutics and translational challenges.
10-sep-2026 novelty 2 per-area 2 strengthens

build build 880 · 2bcef25 · 2026-11-18